Skip to content
Home > Resources & Support

RESOURCES TO SUPPORT YOUR PATIENTS’ ACCESS TO TAZVERIK (tazemetostat)

Download a digital copy of the TAZVERIK Patient Brochure, for disease state and treatment information.

Download

Download the EpizymeNOW patient enrollment form to discuss with your patients and help enroll them in the appropriate support program. Terms and conditions apply.

Download

EpizymeNOW Patient & Product Support

Quick Start
Program

Patient may be eligible to receive medication right away if they experience a delay in the authorization of prescription drug coverage greater than five business days and you have determined there is an immediate medical need to start treatment with TAZVERIK.

Patient Assistance
Program (PAP)

Patient may be eligible to receive free medication if they are uninsured, underinsured (based on program eligibility criteria), enrolled in the Medicare Part D benefit and have coverage for TAZVERIK, but are currently experiencing financial hardship (based on Epizyme's review of appropriate supporting documentation).

See separate patient consent section within the Enrollment Form (Section 9).

Bridge Supply
Program

Patient may be eligible to receive a limited supply of free medication if they experience an unexpected change or disruption in prescription drug coverage or supply (e.g., insurance provider requires a new or updated prior authorization or a change or loss of insurance).

Co-Pay Assistance
Program

For patients with commercial (private) health insurance, eligible to receive co-payment assistance to help reduce out-of-pocket costs for Epizyme medications.

This offer is not valid for cash-paying patients or patients currently enrolled in Medicare, Medicaid, or any other federal or state healthcare program. Limitations apply. Void where prohibited.

Are you a healthcare professional or pharmacy looking to enroll your patient in the EpizymeNOW Co-Pay Assistance Program?

Your commercially-insured patients may be eligible to receive co-pay assistance. Note that only patients' prescribers and specialty pharmacies can register patients for this program.

for healthcare professionals only

Eligibility Criteria

Quick Start
& Bridge Supply
PAP
Co-Pay
Patient has prescription drug coverage either under a commercial (private) health plan or a government program, including Medicare or Medicaid, and they are actively pursuing initial coverage or reauthorization of coverage for TAZVERIK.
Patient meets Epizyme's financial eligibility requirements for enrollment in the Patient Assistance Program based on income and other supporting financial documentation.
Patient currently has commercial (private) health insurance that covers TAZVERIK and no primary or secondary insurance coverage under any state or federal healthcare program, including Medicare or Medicaid.
U.S. residency (including U.S. territories )
Patient has a valid prescription for TAZVERIK
  • Patient insurance coverage for TAZVERIK is delayed for more than five business days, and you have determined there is an immediate medical need to start treatment with TAZVERIK
  • If eligible, a 15-day supply (up to 60 days) of TAZVERIK will be provided to the patient until their prior authorization or coverage request for TAZVERIK is approved.
Patient is currently uninsured or underinsured based on insurance information verification by Epizyme.
 
Quick Start
& Bridge Supply
Patient has prescription drug coverage either under a commercial (private) health plan or a government program, including Medicare or Medicaid, and they are actively pursuing initial coverage or reauthorization of coverage for TAZVERIK.
  • U.S. residency (including U.S. territories )
  • Patient has a valid prescription for TAZVERIK
  • Patient insurance coverage for TAZVERIK is delayed for more than five business days, and you have determined there is an immediate medical need to start treatment with TAZVERIK
  • If eligible, a 15-day supply (up to 60 days) of TAZVERIK will be provided to the patient until their prior authorization or coverage request for TAZVERIK is approved.
PAP
Patient meets Epizyme's financial eligibility requirements for enrollment in the Patient Assistance Program based on income and other supporting financial documentation.
  • U.S. residency (including U.S. territories )
  • Patient has a valid prescription for TAZVERIK
  • Patient is currently uninsured or underinsured based on insurance information verification by Epizyme.
Co-Pay
Patient currently has commercial (private) health insurance that covers TAZVERIK and no primary or secondary insurance coverage under any state or federal healthcare program, including Medicare or Medicaid.
  • U.S. residency (including U.S. territories )
  • Patient has a valid prescription for TAZVERIK

Disclaimer: All patient support is subject to eligibility criteria and program terms and conditions.

See the dosing schedule for patients
taking TAZVERIK.

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

TAZVERIK is indicated for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.

This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

  • Secondary Malignancies

The risk of developing secondary malignancies is increased following treatment with TAZVERIK. Across clinical trials of 729 adults who received TAZVERIK 800 mg twice daily, myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) occurred in 0.7% of patients. One pediatric patient developed T‑cell lymphoblastic lymphoma (T‑LBL). Monitor patients long-term for the development of secondary malignancies.

  • Embryo-Fetal Toxicity

Based on findings from animal studies and its mechanism of action, TAZVERIK can cause fetal harm when administered to pregnant women. There are no available data on TAZVERIK use in pregnant women to inform the drug‑associated risk. Administration of tazemetostat to pregnant rats and rabbits during organogenesis resulted in dose‑dependent increases in skeletal developmental abnormalities in both species beginning at maternal exposures approximately 1.5 times the adult human exposure (area under the plasma concentration time curve [AUC0‑45h]) at the 800 mg twice daily dose.

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TAZVERIK and for 6 months after the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with TAZVERIK and for 3 months after the final dose.

Adverse Reactions

In 62 clinical study patients with epithelioid sarcoma receiving TAZVERIK 800 mg twice daily: Serious adverse reactions occurred in 37% of patients who received TAZVERIK. Serious adverse reactions occurring in ≥3% were hemorrhage, pleural effusion, skin infection, dyspnea, pain, and respiratory distress. The most common (≥20%) adverse reactions were pain (52%), fatigue (47%), nausea (36%), decreased appetite (26%), vomiting (24%), and constipation (21%).

Drug Interactions

Avoid coadministration of strong or moderate CYP3A inhibitors with TAZVERIK. If coadministration of moderate CYP3A inhibitors cannot be avoided, reduce TAZVERIK dose.

Avoid coadministration of moderate and strong CYP3A inducers with TAZVERIK, which may decrease the efficacy of TAZVERIK.

Coadministration of TAZVERIK with CYP3A substrates, including hormonal contraceptives, can result in decreased concentrations and reduced efficacy of CYP3A substrates.

Lactation

Because of the potential risk for serious adverse reactions from TAZVERIK in the breastfed child, advise women not to breastfeed during treatment with TAZVERIK and for one week after the final dose.

Before prescribing TAZVERIK, please read the full Prescribing Information.